Please assess the completion status of the following clinical trial:

Trial Title: Adalimumab in Severe and Acute Sciatica

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients older than 18~2. Episode of radicular pain in one lower limb for less than 12 weeks.~3. Medical evaluation requiring hospitalisation because of pain or functional handicap~4. Patients presenting a characteristic leg pain in the L3, L4, L5, or S1 territories plus at least one of the following: :~   * positive straight-leg-raising test with an elevation of less than 70°~  * positive femoral stretched~  * clear clinical sign of nerve root involvement~     * muscle strength deficiency or~    * sensory disturbances in clear cut dermatome or~    * lower limb reflex asymmetry.~5. Oswestry score greater than 50~6. If there is a past history of radicular pain involving the same nerve root, a 6 months interval free of leg pain is required.~7. A confirmed herniated disc on usual imaging techniques (CT scan or MRI) in the vicinity of the clinically involved nerve root that has been performed within the last 2 years.~8. Written informed consent~Exclusion Criteria:~1. The presence of recent (\<48 hours) severe muscle weakness (\<3/5) or clinical signs of cauda equina compression, requiring immediate surgery.~   * If surgical procedure is required but is denied, either because of surgeon's decision or because of patient's fully informed decision, then this patient could be included in the protocol.~2. Comorbidities such as :~   * Coexisting infections (Chest X-ray will be performed to all patients and tuberculin skin test in case of doubt concerning a past history of tuberculous infection).~  * Autoimmune disease (other than RA).~  * History of cancer or malign lymphoproliferative disorders (unless the patient has been declared in remission for more than 5 years)~  * History of demyelinating disorders.~3. Pregnancy.~4. History of intolerance to adalimumab or any of its ingredients~5. Previous participation in this clinical study.~6. Participation in another clinical study within 4 weeks prior to the start of or during this study.~7. Poor motivation or other emotional or intellectual problems that are likely to limit the ability of the patient to comply with the protocol requirements.~8. The use of cortisone prior to the inclusion IS NOT an exclusion criteria~The investigators will also be allowed to exclude an individual patient from the study and remove the blinding in case of a superimposed infection or any severe side effect during the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab (Type: EXPERIMENTAL): adalimumab (2 subcutaneous 40 mg injections on day 0 and 7)
- Placebo (Type: PLACEBO_COMPARATOR): 2 placebo injections on day 0 and 7

Based on this trial design, predict the completion outcome and termination type (if applicable).